Keywords: مهار کننده آراماتاز; aromatase inhibitor; distant metastasis; endocrine therapy; primary mucinous carcinoma of the skin; ER; estrogen receptor; FDG; [18F]-fluorodeoxy-D-glucose; PET-CT; positron emission tomography-computed tomography; PgR; progesterone receptor; PMCS; prim
مقالات ISI مهار کننده آراماتاز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده آراماتاز; Ovarian cancer; HGSOC; Letrozol maintenance; Aromatase inhibitor; ER;
Keywords: مهار کننده آراماتاز; Breast cancer; Fatigue; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Letrozole; Cattle; Ovulation; Synchronization; Estradiol;
Keywords: مهار کننده آراماتاز; Breast cancer; Extended endocrine therapy; Clinical trial; Compliance; Early treatment discontinuation; Adverse events; Survival; Aromatase inhibitor; Tamoxifen;
Keywords: مهار کننده آراماتاز; AI; aromatase inhibitor; ASCO; American Society of Clinical Oncology; CDK4/6; cyclin-dependent kinase 4/6; DCIS; ductal carcinoma in situ; DFS; disease-free survival; ER; estrogen receptor; FDA; Food and Drug Administration; HER2; human epidermal growth f
Keywords: مهار کننده آراماتاز; Adverse effect; AGEP; Aromatase inhibitor; Cutaneous toxicity; Taxane;
Keywords: مهار کننده آراماتاز; 5-FU; 5-Fluorouracil; AI; aromatase inhibitor; BC; breast cancer; CDK; cyclin-dependent kinase; DHF; dihydrofolate; DHFR; dihydrofolate reductase; ER; estrogen receptor; FSH; follicle stimulating hormone; FDA; Food & Drug Administration; GnRH; gonadotroph
Keywords: مهار کننده آراماتاز; AE; adverse event; AI; aromatase inhibitor; CBT; cognitive behavior therapy; CHC; combined hormonal contraceptive; CNS; central nervous system; DHEA; dehydroepiandrosterone; DSDS; Decreased Sexual Desire Screener; HCP; health care professional; HSDD; hypo
Keywords: مهار کننده آراماتاز; Extended Endocrine Therapy; Breast cancer; Estrogen receptor; Late recurrence; Tamoxifen; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Ovarian anaplastic ependymoma;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Breast cancer; Extended adjuvant; Subgroup;
Keywords: مهار کننده آراماتاز; Antiestrogen; Tamoxifen; SERMs; Aromatase inhibitor; Breast cancer; Lung cancer;
Keywords: مهار کننده آراماتاز; AI; aromatase inhibitor; DHEA; dehydroepiandrosterone; ET; estrogen therapy; FDA; US Food and Drug Administration; GSM; genitourinary syndrome of menopause; SERM; selective estrogen receptor modulator;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Microdosing clinical trial; Cassette dosing approach; LC-MS/MS; Pharmacokinetic properties; First in human study;
Keywords: مهار کننده آراماتاز; Aromatase Inhibitor; Hypoactive Sexual Desire Disorder; Breast Cancer; Fecal Incontinence;
Keywords: مهار کننده آراماتاز; AI; aromatase inhibitor; AR; androgen receptor; CAF; cancer-associated fibroblast; CBR; clinical benefit rate; CDK; cyclin-dependent kinase; ctDNA; circulating tumor DNA; DNMT3B; DNA methyltransferase 3B; ER; estrogen receptor; ESR1; ER gene; HDAC1; histo
Keywords: مهار کننده آراماتاز; Letrozole; Aromatase inhibitor; Male reproduction; Hypergycemia; Insulin signaling; Estradiol;
Keywords: مهار کننده آراماتاز; Aromatase; Estrogen; Inflammation; Breast cancer; Aromatase inhibitor; Endocrine disruption;
Keywords: مهار کننده آراماتاز; AI; aromatase inhibitor; BMD; bone mineral density; BMI; body mass index; Bone; Breast cancer; Chemotherapy; Multiple myeloma; Prostate cancer; Denosumab; Zoledronic acid;
Keywords: مهار کننده آراماتاز; aromatase inhibitor; breast cancer; gynecology; tomoxifen;
Keywords: مهار کننده آراماتاز; 3-BC; 3-benzylidene camphor; 4-MBC; 4-methylbenzylidene camphor; Aβ; amyloid-β; ABAD; Aβ-binding alcohol dehydrogenase; AD; Alzheimer's disease; AI; aromatase inhibitor; AKR; aldo-keto reductase; AME; apparent mineralocorticoid excess; AR; androgen r
Keywords: مهار کننده آراماتاز; Breast cancer; LH-RH agonists; Endocrine therapy; Infertility; Ovarian ablation; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Letrozole; Cattle; Ovulation; Synchronization; Estradiol
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Molecular docking; Rhizopus oryzae; Formestane; Biotransformation; Cytochrome P450 monooxygenase
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Hormone therapy; Indirect treatment comparison; Progression; Selective estrogen receptor degrader;
Keywords: مهار کننده آراماتاز; Circulating tumor cells (CTC); Breast cancer; Hormone receptor positive; Fulvestrant; Aromatase inhibitors; AI; aromatase inhibitor; BCL2; B-cell lymphoma 2; CCS; charcoal stripped calf serum; CTC; circulating tumor cells; EpCAM; epithelial cell adhesion
Keywords: مهار کننده آراماتاز; aromatase inhibitor; endometrial receptivity; implantation; menstrual cycle; premature ovarian insufficiency; random start stimulation;
Keywords: مهار کننده آراماتاز; Breast epithelium; Estradiol concentration; Tamoxifen; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; HPG axis; Compensation responses; Zebrafish; Prochloraz; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Letrozole; Synchronization; Ovarian function; Cattle
Keywords: مهار کننده آراماتاز; Breast cancer; HER-2-negative; Resistance; Biologic targeted agent; Combination therapy; ABC; advanced breast cancer; AE; adverse event; AI; aromatase inhibitor; AKT; protein kinase; BC; breast cancer; CDK; cyclin-dependent kinase; CT; chemotherapy; CTLA;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Discontinuous therapy; Disease resistance;
Keywords: مهار کننده آراماتاز; Endometriosis; Aromatase inhibitor; Endometriosis-related pain
Keywords: مهار کننده آراماتاز; Anastrozole treatment efficacy, Aromatase inhibitor; Aromatase inhibitor; Association of BMI and AI plasma concentrations; Breast cancer; BMI; Levels
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Laparoscopy; Letrozole; Myomas; Myomectomy;
Keywords: مهار کننده آراماتاز; Breast cancer; Aromatase inhibitor; Tamoxifen; Arthralgia; IGF-I; Oestrogens;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Endocrine adjuvant therapy; Estradiol; Luteinizing hormone - Releasing hormone (LHRH) agonists;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Letrozole; Estrogen; Steroid receptor coactivator-1; Neuroendocrine; Adverse effects;
Keywords: مهار کننده آراماتاز; Physical activity; Arthralgia; Aromatase inhibitor
Keywords: مهار کننده آراماتاز; Zebrafish; Estrogen; Cartilage; Craniofacial; Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; Testosterone Pellets; Aromatase Inhibitor; Hypogonadism; Testosterone Deficiency Syndrome;
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; Chelydra serpentina; Chrysemys picta; Environmental sex determination; Sex steroids; Sexual differentiation
Keywords: مهار کننده آراماتاز; Letrozole; Medaka (Oryzias latipes); Cytochrome P450 (CYP); Aromatase inhibitor;
Keywords: مهار کننده آراماتاز; AI; aromatase inhibitor; AR; androgen receptor; ARE; androgen-response element; DDC; l-DOPA decarboxylase; DHT; dihydrotestosterone; ER; estrogen receptor α; ERE; estrogen-response element; E2; estradiol; GFP; green fluorescent protein; LI; labeling inde
Keywords: مهار کننده آراماتاز; Breast Cancer; Aromatase Inhibitor; Sexual Dysfunction; Medication Adherence
Keywords: مهار کننده آراماتاز; 3D; 3-dimensional; ABUS; automated whole-breast ultrasonography; AI; aromatase inhibitor; BI-RADS; Breast Imaging Reporting and Data System; BMI; body mass index; HT; hormone therapy; MBI; molecular breast imaging; MRI; magnetic resonance imaging; US; ult
Keywords: مهار کننده آراماتاز; Sex difference; Impulsivity; Impulsive choice; Neonatal; Organizational effect; Testosterone; Estradiol; Dihydrotestosterone; Aromatase inhibitor; Prefrontal cortex;
Keywords: مهار کننده آراماتاز; Risk-reducing salpingo-oophorectomy; Sexuality; BRCA1/2; Mastectomy; Tamoxifen; Aromatase inhibitor
Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: AÂ Retrospective Review
Keywords: مهار کننده آراماتاز; Aromatase inhibitor; GnRH analog; Ovarian suppression;